ArticleCancer cell international2025
Natural compound triptolide induces caspase-3/GSDME-mediated pyroptosis by promoting ROS accumulation in small cell lung cancer.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol-Inspired Approach.Basic & clinical pharmacology & toxicology · 2026Article
- The dual role of pyroptosis in prostate cancer: new perspectives from molecular mechanisms to clinical translation.Molecular biology reports · 2026Review
- Tripterygium glycosides: recent advances in mechanisms, therapeutic applications, and safety optimization.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSmall cell lung cancer (SCLC) is a highly aggressive malignancy with limited therapeutic options. Triptolide (TPL), a natural compound derived from the traditional Chinese herbal medicine Tripterygium wilfordii Hook F., exhibits broad antitumor effects. However, its role in SCLC remains unexplored.
methodsWe evaluated the effects of TPL on SCLC cell proliferation, migration, and invasion through in vitro assays, including Cell Counting Kit-8, clonogenic, 5-ethynyl-2'-deoxyuridine, cell cycle, and Transwell assays. To predict the potential antitumor targets of TPL against SCLC, we performed a network pharmacology analysis. Pyroptosis was examined by morphological observation, lactate dehydrogenase release assay, and Western blot analysis. The in vivo role of TPL was confirmed using a mouse xenograft model and immunohistochemical assays.
resultsTPL inhibited proliferation, triggered cell cycle arrest at the S-phase, and concomitantly produced a dose-dependent inhibition of SCLC cell invasion and migration. Network pharmacology analysis revealed that the antitumor effect of TPL in SCLC was associated with its potential to regulate inflammatory and apoptotic pathways, indicating the specific mode of cell death induced by TPL in SCLC cells. We confirmed that TPL induces caspase-3/GSDME-mediated pyroptosis in NCI-H1688 and NCI-H1339 cells. Furthermore, TPL induced pyroptosis by promoting reactive oxygen species (ROS) accumulation, whereas ROS inhibition significantly abolished these pyroptotic effects. Additionally, TPL suppressed tumor growth in mice with SCLC xenografts and induced pyroptosis in vivo.
conclusionsThis study demonstrated the antitumor role of TPL in SCLC and its ability to trigger caspase-3/GSDME-mediated pyroptosis through ROS accumulation, providing new insights into SCLC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.